Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
URGN
#2067
UroGen Pharma Ltd. Ordinary Shares
21.700
0
+4.28%
Secteur:
Base:
Devise de Profit:
Range quotidien
Range Annuel
Changement quotidien
+4.28%
Changement Mensuel
-0.60%
Evolution sur 6 mois
+14.21%
Changement Annuel
+14.21%
Clôture Précédente
20.810
0
Open
21.700
0
Bid
Ask
Low
21.700
0
High
21.700
0
Volume
74
Marchés
Actions des Marchés US
Soins de Santé
URGN
Open full chart
Financials
Overview
Relevé
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
22.27 M
22.67 M
23.44 M
34.12 M
46.09 M
—
Valuation ratios
Enterprise value
348.49 M
171.21 M
147.12 M
423.99 M
318.92 M
2.11 B
Price to earnings ratio
—
—
1.79
4.29
3.6
16.97
Price to sales ratio
—
—
3.06
5.3
5.05
26.8
Price to cash flow ratio
—
—
2.25
5.74
4.72
21.28
Price to book ratio
—
—
2.21
6.73
51.87
63.46
Enterprise value to EBITDA ratio
-2.75
-1.87
-1.88
-6.55
-3.3
-17.73
Profitability ratios
Return on assets %
-1.05
-0.93
-0.81
-0.57
-0.44
-0.73
Return on equity %
-1.33
-13.17
-1.23
-1.57
-14.41
-6.03
Return on invested capital %
-1 235.54
-2 006.82
-1 488.99
-1 069.42
-1 457.96
-1 937.33
Gross margin %
91.45
89.27
88.11
88.68
90.18
351.85
Operating margin %
-1 074.15
-192.11
-122.82
-79.23
-107.06
-565.66
EBITDA margin %
-1 074.29
-190.44
-121.42
-78.27
-106.77
-568.25
Net margin %
-1 088.94
-230.67
-170.58
-123.61
-140.35
-696.75
Liquidity ratios
Quick ratio
5.3
4.9
5.21
5.24
5.81
19.06
Current ratio
5.39
5.11
5.39
5.42
6.01
19.79
Inventory turnover
—
—
0.19
0
—
—
Asset turnover
0.07
0.4
0.5
0.53
0.39
0.41
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
0.72
0.55
0.43
2.17
Long term debt to total equity ratio
—
—
-1.09
-1.51
-13.83
-18.83
Per share metrics
Operating cash flow per share
—
—
-3.84
-2.65
-2.26
-2.89
EBIT per share
—
—
-3.47
-2.27
-2.26
-2.82
EBITDA per share
—
—
-3.43
-2.25
-2.25
-2.82
Total debt per share
—
—
—
—
—
—
Cash per share
—
—
4.38
4.91
5.64
15.4
Net current asset value per share
—
—
5.65
5.87
6.44
18.5
Tangible book value per share
—
—
-3.92
-2.26
-0.21
-5.52
Working capital per share
—
—
4.6
4.79
5.37
14.77
Book value per share
—
—
-3.92
-2.26
-0.21
-5.52
Nouvelles
Le directeur médical d’UroGen Pharma vend des actions pour 145k€
UroGen Pharma CMO Schoenberg sells $145k in shares
enGene Holdings: A Potential Oncology Entrant (NASDAQ:ENGN)
2025 Performance Review And Future Strategy
L’action d’Urogen Pharma Ltd atteint un sommet de 52 semaines à 25,2 USD
Urogen Pharma Ltd stock hits 52-week high at 25.2 USD
UroGen Pharma à la conférence Guggenheim : Perspectives stratégiques sur le lancement d’UGN-102
UroGen Pharma at Guggenheim Conference: Strategic Insights into UGN-102 Launch
L’action d’Urogen Pharma atteint un sommet de 52 semaines à 23,66 USD
Urogen Pharma stock hits 52-week high at 23.66 USD
UroGen Pharma Ltd. (URGN) Q3 2025 Earnings Call Transcript
Le titre de l’action UroGen Pharma bondit après des résultats positifs d’essai de phase 3